These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11586114)

  • 1. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.
    Drapalski AL; Rosse RB; Peebles RR; Schwartz BL; Marvel CL; Deutsch SI
    Clin Neuropharmacol; 2001; 24(5):290-4. PubMed ID: 11586114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia.
    Deutsch SI; Schwartz BL; Rosse RB; Mastropaolo J; Marvel CL; Drapalski AL
    Clin Neuropharmacol; 2003; 26(4):199-206. PubMed ID: 12897641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Tiihonen J; Halonen P; Wahlbeck K; Repo-Tiihonen E; Hyvärinen S; Eronen M; Putkonen H; Takala P; Mehtonen OP; Puck M; Oksanen J; Koskelainen P; Joffe G; Aer J; Hallikainen T; Ryynänen OP; Tupala E
    J Clin Psychiatry; 2005 Aug; 66(8):1012-5. PubMed ID: 16086616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate antagonizes MK-801 in an animal model of schizophrenia.
    Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J
    Eur J Pharmacol; 2002 Aug; 449(1-2):121-5. PubMed ID: 12163115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial.
    Afshar H; Roohafza H; Mousavi G; Golchin S; Toghianifar N; Sadeghi M; Talaei M
    J Psychopharmacol; 2009 Mar; 23(2):157-62. PubMed ID: 18515465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.
    Dursun SM; Deakin JF
    J Psychopharmacol; 2001 Dec; 15(4):297-301. PubMed ID: 11769825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
    Gobbi G; Gaudreau PO; Leblanc N
    J Clin Psychopharmacol; 2006 Oct; 26(5):467-73. PubMed ID: 16974186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects.
    Hahn MK; Remington G; Bois D; Cohn T
    J Clin Psychopharmacol; 2010 Dec; 30(6):706-10. PubMed ID: 21105286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate in opiate withdrawal.
    Zullino DF; Cottier AC; Besson J
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1221-3. PubMed ID: 12452551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.
    Hahn MK; Cohn T; Teo C; Remington G
    Clin Schizophr Relat Psychoses; 2013 Jan; 6(4):186-96. PubMed ID: 23302448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design.
    Grunze HC; Normann C; Langosch J; Schaefer M; Amann B; Sterr A; Schloesser S; Kleindienst N; Walden J
    J Clin Psychiatry; 2001 Jun; 62(6):464-8. PubMed ID: 11465524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Bellinghieri PM; Scimeca G; Cacciola M; Campolo D; Settineri S; Zoccali R
    J Psychopharmacol; 2011 May; 25(5):667-74. PubMed ID: 20615930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis?
    Duggal HS
    J Clin Psychiatry; 2004 Aug; 65(8):1145; author reply 1145--6. PubMed ID: 15323603
    [No Abstract]   [Full Text] [Related]  

  • 16. Topiramate for clozapine-induced seizures.
    Navarro V; Pons A; Romero A; Bernardo M
    Am J Psychiatry; 2001 Jun; 158(6):968-9. PubMed ID: 11384919
    [No Abstract]   [Full Text] [Related]  

  • 17. Topiramate for refractory schizophrenia.
    Millson RC; Owen JA; Lorberg GW; Tackaberry L
    Am J Psychiatry; 2002 Apr; 159(4):675. PubMed ID: 11925318
    [No Abstract]   [Full Text] [Related]  

  • 18. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.
    Berlant J; van Kammen DP
    J Clin Psychiatry; 2002 Jan; 63(1):15-20. PubMed ID: 11838620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose lamotrigine augmentation therapy improves residual symptoms in treatment-resistant schizophrenia: a report of five cases.
    Ohnuma T; Takebayashi Y; Higashiyama R; Shibata N; Arai H
    Asia Pac Psychiatry; 2013 Dec; 5(4):336-43. PubMed ID: 24591092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Target pharmacology of topiramate, a new antiepileptic drug].
    Nakamura J; Kuwana Y; Yukitoshi N
    Nihon Yakurigaku Zasshi; 2000 Jan; 115(1):53-7. PubMed ID: 10876816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.